#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	1930	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2512	227.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1602	1602	C	283	C	240	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2960	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3835	230.1	0	.	n	.	0	T695C	SNP	695	695	T	1130	1130	C	190	C,T	155,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2960	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3835	230.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1772	1772	A	267	A,G	221,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2960	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3835	230.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2406	2406	C	302	C,T,A	256,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2960	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3835	230.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3032	3032	T	258	T	222	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2960	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3835	230.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2480	2480	A	316	A	257	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	312	folP	852	852	100.0	folP.l15.c4.ctg.1	1951	47.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1165	1167	AGC	67;68;68	A;G;C	56;58;59	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	572	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3875	44.2	0	.	p	.	0	V857A	NONSYN	2569	2571	GTG	3014	3016	GCG	54;54;53	G;C;G	50;49;48	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	572	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3875	44.2	1	SNP	p	S91F	0	.	.	271	273	TCC	716	718	TCC	52;52;52	T;C;C	43;41;44	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	572	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3875	44.2	1	SNP	p	D95N	0	.	.	283	285	GAC	728	730	GAC	51;51;52	G;A;C	43;43;44	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	572	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3875	44.2	1	SNP	p	D95G	0	.	.	283	285	GAC	728	730	GAC	51;51;52	G;A;C	43;43;44	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	262	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1779	44.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	655	657	ACC	84;84;84	A;C;C,A	67;70;68,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	262	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1779	44.2	0	.	p	.	0	R44H	NONSYN	130	132	CGC	670	672	CAC	81;81;81	C;A;C	66;69;68	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	262	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1779	44.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	853	855	CAC	70;69;69	C;A;C,A	62;60;60,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	262	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1779	44.2	1	SNP	p	G45D	0	.	.	133	135	GGC	673	675	GGC	81;81;81	G;G;C	69;68;67	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	202	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1365	44.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3390	62.0	1	SNP	p	D86N	0	.	.	256	258	GAC	857	859	GAC	82;83;83	G;A;C	65;62;67	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3390	62.0	1	SNP	p	S87R	0	.	.	259	261	AGT	860	862	AGT	81;81;80	A,C;G;T	65,1;65;65	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3390	62.0	1	SNP	p	S87W	0	.	.	259	261	AGT	860	862	AGT	81;81;80	A,C;G;T	65,1;65;65	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3390	62.0	1	SNP	p	S87I	0	.	.	259	261	AGT	860	862	AGT	81;81;80	A,C;G;T	65,1;65;65	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3390	62.0	1	SNP	p	S88P	0	.	.	262	264	TCC	863	865	TCC	80;81;82	T;C,A;C	65;65,1;70	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	572	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2961	57.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1735	1737	GGC	60;60;60	G;G;C,A	50;51;49,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1462	1464	GCA	92;92;91	G;C;A	76;79;79	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1465	1467	ATC	90;90;90	A;T;C,A	76;79;77,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1477	1479	GTG	90;90;89	G;T;G	79;75;77	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1477	1479	GTG	90;90;89	G;T;G	79;75;77	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1981	1983	ACC	62;63;63	A;C;C	52;53;54	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2035	2037	GCG	64;64;64	G;C;G,A	53;51;52,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2035	2037	GCG	64;64;64	G;C;G,A	53;51;52,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2158	2160	GGC	59;59;59	G;G;C	44;48;49	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2167	2169	GGC	58;58;57	G,A;G;C,A,G	46,1;45;46,1,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	502	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2809	53.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2185	2187	CCG	58;58;57	C;C;G	44;49;43	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	698	ponA	2397	2397	99.96	ponA.l6.c17.ctg.1	3500	59.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	328	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2033	47.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	653	653	C	43	C	38	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1229	1231	AAT	7;7;7	A;A;T	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1232	1234	AAT	7;7;7	A;A;T	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1256	1258	GCA	7;7;7	G;C;A	7;6;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1279	1281	GTA	7;6;6	G;T;A	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	.	INDELS	709	710	AA	1289	1293	GTGAG	6;6;6;5;5	G;T;G;A;G	6;6;6;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	D238G	NONSYN	712	714	GAT	1295	1297	GGT	5;5;5	G;G;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	A251V	NONSYN	751	753	GCG	1334	1336	GTA	4;4;4	G;T;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	S271T	NONSYN	811	813	TCG	1394	1396	ACT	5;5;5	A;C;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	1400	1402	GAT	5;5;5	G;A;T	3;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	D276N	NONSYN	826	828	GAT	1409	1411	AAC	5;5;5	A;A;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	58	porB1a	984	297	91.03	porB1a.l15.c4.ctg.1	1502	11.3	0	.	p	.	0	N277H	NONSYN	829	831	AAC	1412	1414	CAC	5;5;5	C;A;C	4;4;4	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	0	.	p	.	0	I45V	NONSYN	133	135	ATT	611	613	GTT	76;76;77	G;T;T	66;64;68	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	0	.	p	.	0	I75V	NONSYN	223	225	ATT	701	703	GTT	79;79;79	G;T;T	69;67;67	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	0	.	p	.	0	S89T	NONSYN	265	267	AGC	743	745	ACC	82;82;81	A;C;C	67;71;67	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	0	.	p	.	0	I98V	NONSYN	292	294	ATC	770	772	GTC	81;81;81	G;T;C	67;69;69	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	878	880	GAT	86;86;85	G;A,G;T	69;68,1;69	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	0	.	p	.	0	M254V	NONSYN	760	762	ATG	1238	1240	GTG	82;82;82	G;T;G	72;72;72	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	1	SNP	p	G120K	1	.	.	358	360	AAG	836	838	AAG	84;85;85	A;A;G	70;71;68	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	1	SNP	p	A121N	1	.	.	361	363	AAC	839	841	AAC	86;87;87	A;A;C	71;72;72	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	378	porB1b	1038	1038	99.33	porB1b.l15.c4.ctg.1	1799	61.9	1	SNP	p	N121D	0	.	.	361	363	AAC	839	841	AAC	86;87;87	A;A;C	71;72;72	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1350	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5262	76.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2113	2115	AAT	81;81;81	A;A;T	65;67;65	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	212	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1517	42.0	1	SNP	p	V57M	1	.	.	169	171	ATG	730	732	ATG	83;83;83	A;T;G	67;68;67	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
